Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) and CERo Therapeutics (NASDAQ:CERO – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, risk, dividends and valuation.
Valuation & Earnings
This table compares Xenetic Biosciences and CERo Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Xenetic Biosciences | $2.50 million | 2.02 | -$3.96 million | ($2.05) | -1.08 |
| CERo Therapeutics | N/A | N/A | -$8.30 million | ($102.61) | 0.00 |
Analyst Ratings
This is a summary of current ratings for Xenetic Biosciences and CERo Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Xenetic Biosciences | 1 | 1 | 0 | 0 | 1.50 |
| CERo Therapeutics | 1 | 3 | 0 | 0 | 1.75 |
CERo Therapeutics has a consensus price target of $45.00, indicating a potential upside of 86,438.46%. Given CERo Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe CERo Therapeutics is more favorable than Xenetic Biosciences.
Insider & Institutional Ownership
15.1% of Xenetic Biosciences shares are held by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are held by institutional investors. 7.6% of Xenetic Biosciences shares are held by insiders. Comparatively, 0.4% of CERo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Xenetic Biosciences and CERo Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Xenetic Biosciences | -110.42% | -64.66% | -54.63% |
| CERo Therapeutics | N/A | N/A | -209.40% |
Risk and Volatility
Xenetic Biosciences has a beta of 2.25, meaning that its share price is 125% more volatile than the S&P 500. Comparatively, CERo Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
About CERo Therapeutics
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.
Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
